A phase IIa multi-dose study in cirrhotic patients using a tablet formulation to determine the steady-state pharmacokinetics and pharmacodynamics of OCR-002

Trial Profile

A phase IIa multi-dose study in cirrhotic patients using a tablet formulation to determine the steady-state pharmacokinetics and pharmacodynamics of OCR-002

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Ornithine phenylacetate (Primary)
  • Indications Hepatic encephalopathy
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 01 Jun 2017 According to an Ocera Therapeutics media release, the first patient has been dosed in this trial.
    • 01 Jun 2017 According to an Ocera Therapeutics media release, status changed from planning to recruiting.
    • 12 Apr 2017 According to an Ocera Therapeutics media release, the company plans to initiate this trial in the second quarter of 2017 and expects data by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top